We are live on ! Find out more
VCYT icon

Veracyte

232 hedge funds and large institutions have $1.96B invested in Veracyte in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 91 increasing their positions, 82 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

13% more capital invested

Capital invested by funds: $1.74B → $1.96B (+$222M)

11% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 82

4% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 24

0% more funds holding

Funds holding: 232232 (0)

2.64% less ownership

Funds ownership: 109.06%106.42% (-2.6%)

58% less call options, than puts

Call options by funds: $252K | Put options by funds: $593K

Holders
232
Holders Change
Holders Change %
0%
% of All Funds
3.64%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
25
Increased
91
Reduced
82
Closed
24
Calls
$252K
Puts
$593K
Net Calls
-$341K
Net Calls Change
-$791K
Name Holding Trade Value Shares
Change
Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$15.4M +$6.01M +247,913 +70%
CS
27
Candriam SCA
Luxembourg
$15.3M -$514K -21,220 -3%
GIM
28
Granahan Investment Management
Massachusetts
$15.1M -$13.4M -553,845 -48%
Mirae Asset Global Investments
29
Mirae Asset Global Investments
South Korea
$13.1M +$909K +37,514 +8%
OAM
30
Oberweis Asset Management
Illinois
$12.3M +$6.55M +270,130 +127%
AAMU
31
AEGON Asset Management (UK)
United Kingdom
$11.4M +$2.07M +85,460 +24%
DCM
32
Driehaus Capital Management
Illinois
$10.5M +$359K +14,807 +4%
Invesco
33
Invesco
Georgia
$8.76M -$1.09M -45,056 -12%
Legal & General Group
34
Legal & General Group
United Kingdom
$8.13M +$569K +23,469 +8%
Prudential Financial
35
Prudential Financial
New Jersey
$7.83M -$1.58M -65,262 -18%
CCP
36
Clough Capital Partners
Massachusetts
$7.04M -$1.54M -63,718 -19%
JP Morgan Chase
37
JP Morgan Chase
New York
$6.85M +$4.27M +176,275 +190%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$6.56M +$101K +4,178 +2%
SBH
39
Segall Bryant & Hamill
Illinois
$6.54M +$49.3K +2,034 +0.8%
EAM
40
EFG Asset Management
Oregon
$6.3M -$559K -23,080 -9%
Rafferty Asset Management
41
Rafferty Asset Management
New York
$6.2M -$1.15M -47,344 -16%
SCM
42
Silverarc Capital Management
Massachusetts
$5.84M +$480K +19,798 +9%
Voloridge Investment Management
43
Voloridge Investment Management
Florida
$5.53M -$3.7M -152,766 -41%
PHP
44
Parkman Healthcare Partners
Connecticut
$5.4M +$2.26M +93,338 +79%
Citadel Advisors
45
Citadel Advisors
Florida
$5.3M -$22.7M -934,459 -82%
Norges Bank
46
Norges Bank
Norway
$5.2M -$6.79M -280,300 -58%
EIM
47
Essex Investment Management
Massachusetts
$4.79M +$344K +14,200 +8%
Barclays
48
Barclays
United Kingdom
$4.51M +$764K +31,517 +22%
Ameriprise
49
Ameriprise
Minnesota
$4.43M +$1.2M +49,558 +40%
Envestnet Asset Management
50
Envestnet Asset Management
Illinois
$4.38M -$12.1M -497,672 -74%

VCYT Hedge Fund Activity: Q2 2023 in Review

232 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q2 2023, worth a combined $1.96B — up 13% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new VCYT positions and 24 closed out — a net gain of 1 holder — while 91 added to existing stakes and 82 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $27.1M. The largest seller was Citadel Advisors, cutting an estimated $22.7M.

  • 232 institutional investors held Veracyte (VCYT) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $1.96B of Veracyte stock for Q2 2023, up 13% quarter-over-quarter.
  • 25 funds opened new Veracyte positions in Q2 2023 and 24 closed out, a net change of +1 holder.
  • The largest Veracyte buyer in Q2 2023 was Point72 Asset Management, an estimated $27.1M added.
  • The largest Veracyte seller in Q2 2023 was Citadel Advisors, an estimated $22.7M sold.

Based on aggregated 13F filings for Q2 2023.